FindTrial
Sign In

An single center, randomized, double-blind , placebo-controlled and Dose-Escalation Phase 1 Study to Evaluate the Safety Tolerability and PK of SMR001 in Chinese healthy volunteer

An single center, randomized, double-blind , placebo-controlled and Dose-Escalation Phase 1 Study to Evaluate the Safety Tolerability and PK of SMR001 in Chinese healthy volunteer

Status
Active, not recruiting
Phases
Phase 1
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2000040127
Enrollment
Unknown
Registered
2020-11-22
Start date
2020-11-20
Completion date
Unknown
Last updated
2021-01-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

xerophthalmia

Interventions

single dose:10 20 40 20 40 80 120 180ug/ml
multiple dose:40 80 180ug/ml:NA

Sponsors

West China hospital, Sichuan University
Lead Sponsor

Eligibility

Sex/Gender
Male

Inclusion criteria

Inclusion criteria: Aged 18 to 45 years health men and women.

Exclusion criteria

Exclusion criteria: N/A

Design outcomes

Primary

MeasureTime frame
laboratory examination;—

Countries

China

Contacts

Public ContactQi Shen

West China Hospital, Sichuan University

769824157@qq.com+86 13228212376

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026